ANI Pharmaceuticals, Inc.
Financials
Valuation Metrics
ANI Pharmaceuticals, Inc.'s Market Cap is $1.61B. At end of 2025 it was $1.58B. Ranked #2120 of 3,116 in US market (top 68%), #821 of 1,472 on NASDAQ (top 56%), #149 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 56%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.61B | US#2,120/3,116 Sec#149/265 |
| Revenue | $978M | US#1,879/3,116 Sec#53/265 |
| Net Income | $106M | US#1,588/3,116 Sec#54/265 |
| Total Assets | $1.49B | US#2,257/3,116 Sec#69/265 |
| Net Assets | $597M | US#2,099/3,116 Sec#96/265 |
| Employees | 970 | US#1,991/3,116 Sec#55/265 |
| Value | ||
| P/E | 15.19x | US#822/3,116 Sec#26/265 |
| P/B | 2.69x | US#1,669/3,116 Sec#90/265 |
| P/S | 1.64x | US#1,135/3,116 Sec#24/265 |
| EV/EBITDA | 6.17x | US#315/3,116 Sec#9/265 |
| FCF Yield | 9.92% | US#621/3,116 Sec#19/265 |
| Profitability | ||
| ROE | 17.72% | US#718/3,116 Sec#38/265 |
| ROA | 7.08% | US#781/3,116 Sec#45/265 |
| Op. Margin | 15.35% | US#1,170/3,116 Sec#51/265 |
| Revenue Growth | 30.90% | US#401/3,116 Sec#61/265 |
| Financial Health | ||
| Debt Ratio | 150.18% | US#1,496/3,116 Sec#187/265 |
| Total Debt | $330M | US#2,059/3,116 Sec#76/265 |
| FCF | $159M | US#1,509/3,116 Sec#54/265 |
| Cash | $360M | US#1,283/3,116 Sec#71/265 |
| Current Ratio | 2.91x | US#811/3,116 Sec#194/265 |
| Net Debt/EBITDA | -0.12x | US#526/3,116 Sec#29/265 |
| Performance | ||
| 1Y Return | -21.98% | US#2,422/3,116 Sec#196/265 |
| 1M Return | -2.06% | US#1,775/3,116 Sec#121/265 |
| From 52W High | -26.03% | US#1,710/3,116 Sec#101/265 |
| 1Y MDD | -25.74% | US#999/3,116 Sec#44/265 |
| Trading | ||
| Volume | 360,263 shares | US#2,659/3,116 Sec#248/265 |
| Trading Value | $26M | US#2,092/3,116 Sec#166/265 |
| Per Share | ||
| EPS | $4.65 | US#739/3,116 Sec#21/265 |
| BPS | $26.27 | US#1,001/3,116 Sec#21/265 |
Company Info
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.